Bristol-Myers Squibb Company (BMY)
$
60.99
+0.97 (1.59%)
Key metrics
Financial statements
Free cash flow per share
6.8713
Market cap
124.1 Billion
Price to sales ratio
2.5694
Debt to equity
3.1344
Current ratio
1.2526
Income quality
-1.6997
Average inventory
2.9 Billion
ROE
-0.5344
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, and marketing of biopharmaceutical products on a global scale, focusing on multiple therapeutic areas including hematology, oncology, cardiovascular diseases, immunology, fibrotic conditions, neuroscience, and COVID-19. The company's diverse portfolio features Revlimid, an oral immunomodulatory agent for treating multiple myeloma; Eliquis, an oral anticoagulant reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) while also treating DVT and PE; and Opdivo, which is utilized for various anti-cancer indications. Other prominent products include Pomalyst/Imnovid for multiple myeloma patients, Orencia for adults with active rheumatoid arthritis and psoriatic arthritis, and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. Additionally, Yervoy addresses unresectable or metastatic melanoma, while Abraxane serves as a protein-bound chemotherapy option. Reblozyl treats anemia in adults with beta thalassemia, and Empliciti is indicated for multiple myeloma treatment. The company further extends its offerings with Zeposia for relapsing forms of multiple sclerosis, Breyanzi as a CD19-directed autologous T cell therapy for relapsed or refractory large B-cell lymphoma in adults, Inrebic, an oral kinase inhibitor for myelofibrosis, and Onureg for acute myeloid leukemia in adults. It distributes its products through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government entities. The company recorded an operating income of $0.00 reflecting its earnings from core operations, with a cost of revenue amounting to $11,949,000,000.00 showcasing its production and operational expenses. The income before tax ratio is -0.17 depicting the pre-tax margin, while a significant net income of -$8,948,000,000.00 illustrates the company’s strong financial health. Additionally, the net income ratio stands at -0.19 reflecting the company's profitability margin. In the realm of market positioning, the stock is reasonably priced at $61.51 appealing to a broad range of investors. It has a high average trading volume of 11,682,773.00 indicating strong liquidity and a robust trading interest among stakeholders. With a large market capitalization of $124,100,012,400.00 the company emerges as a dominant player within the biopharmaceutical sector. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, consistently driving innovation and growth in its field.
What is Bristol-Myers Squibb Company (BMY)'s stock forecast?
Analysts predict Bristol-Myers Squibb Company stock to fluctuate between $39.35 (low) and $63.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Bristol-Myers Squibb Company's market capitalization?
As of 2025-04-01, Bristol-Myers Squibb Company's market cap is $124,100,012,400, based on 2,034,760,000 outstanding shares.
How does Bristol-Myers Squibb Company compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Bristol-Myers Squibb Company has a Lower Market-Cap, indicating a difference in performance.
How can I buy Bristol-Myers Squibb Company (BMY) stock?
To buy Bristol-Myers Squibb Company (BMY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BMY. Place an order (Market, Limit, etc.).
What is the best time to invest in Bristol-Myers Squibb Company?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Bristol-Myers Squibb Company perform in the last earnings report?
Revenue: $48,300,000,000 | EPS: -$4.41 | Growth: -213.66%.
Where can I find Bristol-Myers Squibb Company's investor relations reports?
Visit https://www.bms.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Bristol-Myers Squibb Company?
You can explore historical data from here
What is the all-time high and low for Bristol-Myers Squibb Company stock?
All-time high: $81.44 (2022-12-01) | All-time low: $39.35 (2024-07-05).
What are the key trends affecting Bristol-Myers Squibb Company stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.
seekingalpha.com
Merck and Bristol-Myers Squibb occupy leading positions in the cancer therapy market. Each of them has advantages, as well as dark spots in the portfolio of medications relative to the comparator. In this article, dear Seeking Alpha readers, you will learn whether Merck or Bristol-Myers Squibb is a more promising stock in the long term.
seekingalpha.com
I reiterate my "Buy" rating on Bristol-Myers Squibb due to its undervaluation, strong growth portfolio, and significant cost-saving initiatives. BMY's drug portfolio expansion and strategic productivity initiatives are expected to sustain high EBITDA margins and drive future top-line growth. Despite legacy drug challenges, BMY's growth portfolio shows robust revenue acceleration, with a projected fair value per share of $70.35, offering a 17.25% upside.
seekingalpha.com
Bristol-Myers Squibb Company (NYSE:BMY ) Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ET Company Participants Roland Chen - Head of Development for Immunology, Cardiology & Neuroscience Conference Call Participants David Risinger - Leerink Partners David Risinger Great. So, good morning everybody.
prnewswire.com
NEW YORK , March 11, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. (NASDAQ: TSVT) and its board of directors concerning the proposed acquisition of the company by Bristol Myers Squibb (NYSE: BMY). Stockholders will receive $5.00 for each share of 2seventy bio stock that they hold.
benzinga.com
On Monday, Bristol Myers Squibb & Co BMY agreed to acquire 2seventy bio, Inc. TSVT at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. “A year ago, 2seventy decided to exc.
247wallst.com
The last time the economy experienced two negative quarters of gross domestic product was the first and second quarters of 2022, with a 1.6% pullback in the first quarter and a 0.6% decline in the second.
businesswire.com
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AAD--Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared.
zacks.com
Bristol Myers Squibb (BMY) concluded the recent trading session at $60.18, signifying a +0.6% move from its prior day's close.
See all news
